Published in Ann Neurol on September 01, 1994
Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res (2006) 1.50
Glutathione metabolism and Parkinson's disease. Free Radic Biol Med (2013) 1.20
Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm (Vienna) (1997) 1.18
Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. AAPS J (2006) 1.09
The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability. Neurogenetics (2007) 1.07
Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Sci (2008) 1.06
Mitochondrial neuronal uncoupling proteins: a target for potential disease-modification in Parkinson's disease. Transl Neurodegener (2012) 1.06
Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. Exp Brain Res (2006) 0.98
Nonselenium glutathione peroxidase in human brain : elevated levels in Parkinson's disease and dementia with lewy bodies. Am J Pathol (2002) 0.95
Novel insights into eukaryotic γ-glutamyltranspeptidase 1 from the crystal structure of the glutamate-bound human enzyme. J Biol Chem (2013) 0.93
Lack of glutathione peroxidase-1 exacerbates Abeta-mediated neurotoxicity in cortical neurons. J Neural Transm (Vienna) (2005) 0.90
Up-regulation of gamma-glutamyl transpeptidase activity following glutathione depletion has a compensatory rather than an inhibitory effect on mitochondrial complex I activity: implications for Parkinson's disease. Free Radic Biol Med (2006) 0.89
6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. Cell Mol Neurobiol (2001) 0.87
Molecular events underlying Parkinson's disease - an interwoven tapestry. Front Neurol (2013) 0.86
Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. J Neural Transm (Vienna) (1997) 0.83
The Role of skn-1 in methylmercury-induced latent dopaminergic neurodegeneration. Neurochem Res (2013) 0.82
Epalrestat increases intracellular glutathione levels in Schwann cells through transcription regulation. Redox Biol (2013) 0.80
Mesencephalic neuron death induced by congeners of nitrogen monoxide is prevented by the lazaroid U-83836E. Exp Brain Res (1997) 0.76
Parkinson's Disease: The Mitochondria-Iron Link. Parkinsons Dis (2016) 0.76
Astrocytes Surviving Severe Stress Can Still Protect Neighboring Neurons from Proteotoxic Injury. Mol Neurobiol (2015) 0.76
The brain on fire? Ann Neurol (1994) 0.75
Sustained Effects of Neonatal Systemic Lipopolysaccharide on IL-1β and Nrf2 in Adult Rat Substantia Nigra Are Partly Normalized by a Spirulina-Enriched Diet. Neuroimmunomodulation (2016) 0.75
Enhanced Neuroprotective Effects of Coadministration of Tetrandrine with Glutathione in Preclinical Model of Parkinson's Disease. Parkinsons Dis (2015) 0.75
Effect of pH on the hydrolytic kinetics of gamma-glutamyl transferase from Bacillus subtilis. ScientificWorldJournal (2014) 0.75
Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration? Antioxidants (Basel) (2017) 0.75
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1988) 14.72
Corticocortical inhibition in human motor cortex. J Physiol (1993) 8.92
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
A film of patients with movement disorders made in Queen Square, London in the Mid-1920s by Samuel Alexander Kinnier Wilson. Mov Disord (2011) 6.45
What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology (1992) 6.03
Mitochondrial complex I deficiency in Parkinson's disease. Lancet (1989) 5.72
Electric and magnetic stimulation of human motor cortex: surface EMG and single motor unit responses. J Physiol (1989) 5.69
Servo action in the human thumb. J Physiol (1976) 4.93
Interhemispheric inhibition of the human motor cortex. J Physiol (1992) 4.77
Servo action in human voluntary movement. Nature (1972) 4.33
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem (1990) 4.03
Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry (2000) 3.89
Striatonigral degeneration. A clinicopathological study. Brain (1990) 3.70
Painful legs and moving toes. Brain (1971) 3.63
Validity and reliability of a rating scale for the primary torsion dystonias. Neurology (1985) 3.56
The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain (1994) 3.54
Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry (1989) 3.53
Writers' cramp-a focal dystonia. Brain (1982) 3.43
Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms. BMJ (1998) 3.41
Outcome of investigation of patients with presenile dementia. Br Med J (1972) 3.39
Neuropathological features of Alzheimer's disease in non-demented parkinsonian patients. J Neurol Neurosurg Psychiatry (1991) 3.38
Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science (1990) 3.31
Stretch reflex and servo action in a variety of human muscles. J Physiol (1976) 3.29
Scope of a technique for electrical stimulation of human brain, spinal cord, and muscle. Lancet (1982) 3.26
The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology (1982) 3.26
Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology (2001) 3.25
Corticobasal degeneration. Brain (1989) 3.20
Stimulation of the human motor cortex through the scalp. Exp Physiol (1991) 3.16
The impact of treatment with levodopa on Parkinson's disease. Q J Med (1980) 3.14
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology (2008) 3.10
Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology (2011) 3.10
A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol (1993) 3.00
Peripheral beta-adrenergic receptors concerned with tremor. Clin Sci (1967) 2.97
The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med (1980) 2.81
Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet (1988) 2.80
Motor cortex stimulation in intact man. 2. Multiple descending volleys. Brain (1987) 2.77
Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol (1995) 2.76
Classification of dystonia. Adv Neurol (1998) 2.75
Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry (1988) 2.74
Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia? J Neurol Neurosurg Psychiatry (1976) 2.72
Cognitive deficits in the early stages of Parkinson's disease. Brain (1983) 2.65
Human walking and higher-level gait disorders, particularly in the elderly. Neurology (1993) 2.65
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain (1992) 2.64
Manual motor performance in a deafferented man. Brain (1982) 2.63
The anatomical basis of symptomatic hemidystonia. Brain (1985) 2.60
Is the human stretch reflex cortical rather than spinal? Lancet (1973) 2.58
Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet (2005) 2.56
"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet (1976) 2.54
Movement disorders in multiple sclerosis. Mov Disord (1995) 2.53
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
The pathophysiology of primary dystonia. Brain (1998) 2.51
Pathophysiology of blepharospasm and oromandibular dystonia. Brain (1985) 2.50
A method of monitoring function in corticospinal pathways during scoliosis surgery with a note on motor conduction velocities. J Neurol Neurosurg Psychiatry (1986) 2.50
PINK1 protein in normal human brain and Parkinson's disease. Brain (2006) 2.49
Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry (1988) 2.46
Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (1990) 2.45
Changes in the response to magnetic and electrical stimulation of the motor cortex following muscle stretch in man. J Physiol (1991) 2.44
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 2.42
Attitudes of families to some aspects of Huntington's chorea. Psychol Med (1979) 2.40
A study of hereditary essential tremor. Brain (1994) 2.37
Focal dystonia of the jaw and the differential diagnosis of unilateral jaw and masticatory spasm. J Neurol Neurosurg Psychiatry (1986) 2.37
'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain (1988) 2.36
The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology (1997) 2.36
Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology (1992) 2.36
Disturbance of sequential movements in patients with Parkinson's disease. Brain (1987) 2.30
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet (1990) 2.30
Postural electromyographic responses in the arm and leg following galvanic vestibular stimulation in man. Exp Brain Res (1993) 2.30
Abnormalities in central motor pathway conduction in multiple sclerosis. Lancet (1984) 2.30
Isolated single motor units in human muscle and their rate of discharge during maximal voluntary effort. J Physiol (1971) 2.28
Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl (1993) 2.27
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26
Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (1998) 2.22
Spinal internuncial neurones in progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (1979) 2.20
Critical phosphorylation sites for acetyl-CoA carboxylase activity. J Biol Chem (1994) 2.19
Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry (1998) 2.19
Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology (2000) 2.19
Delay in the execution of voluntary movement by electrical or magnetic brain stimulation in intact man. Evidence for the storage of motor programs in the brain. Brain (1989) 2.19
The sensory mechanism of servo action in human muscle. J Physiol (1977) 2.18
Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. J Neurol Neurosurg Psychiatry (1976) 2.18
Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet (1997) 2.16